Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

Conventional Prophylactic Oral Dexamethasone vs Short-course IV Dexamethasone in Paclitaxel Hypersensitivity

Phase 3

Recruiting

Conditions: Hypersensitivity Reactions

Interventions: Drug: Dexamethasone

First Posted Date: 2018-07-26

Last Posted Date: 2024-07-01

Lead Sponsor: Loma Linda University

Target Recruit Count: 270

Registration Number: NCT03598426

Locations: 🇺🇸
Loma Linda University Cancer Center, Loma Linda, California, United States

The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing Chemotherapy

Not Applicable

Conditions: Chemotherapy-induced Nausea and Vomiting

Interventions: Drug: Dexamethasone
Drug: Thalidomide
Drug: 5-HT3 antagonists

First Posted Date: 2018-07-26

Last Posted Date: 2018-07-26

Lead Sponsor: Yunpeng Liu

Target Recruit Count: 880

Registration Number: NCT03601871

Locations: 🇨🇳
Fushun Central Hospital, Fushun, Liaoning, China
🇨🇳
cancer hospital of Haerbin Medical University, Haerbin, Heilongjiang, China
🇨🇳
Siping City Cancer Hospital, Siping, Jilin, China

and more 26 locations

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

Phase 1

Withdrawn

Conditions: Plasma Cell Leukemia

Interventions: Drug: Bortezomib
Biological: Daratumumab
Drug: Dexamethasone
Drug: Lenalidomide
Drug: Pegylated Liposomal Doxorubicin Hydrochloride

First Posted Date: 2018-07-19

Last Posted Date: 2018-12-19

Lead Sponsor: City of Hope Medical Center

Registration Number: NCT03591744

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States
🇺🇸
Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States

and more 2 locations

Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Relapsed/Refractory Multiple Myeloma

Interventions: Drug: Ixazomib
Drug: Pomalidomide
Drug: Dexamethasone
Drug: Daratumumab-Hyaluronidase-Fihj@1,800 Mg-30,000 Unit/15 mL@SUBCUT@VIAL (ML)

First Posted Date: 2018-07-18

Last Posted Date: 2024-05-01

Lead Sponsor: University of California, San Diego

Target Recruit Count: 46

Registration Number: NCT03590652

Locations: 🇺🇸
UCSD Moores Cancer Center, La Jolla, California, United States

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Phase 3

Active, not recruiting

Conditions: Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

Interventions: Drug: Ponatinib
Drug: Imatinib
Drug: Vincristine
Drug: Dexamethasone
Drug: Cytarabine
Drug: Methotrexate
Drug: Prednisone

First Posted Date: 2018-07-17

Last Posted Date: 2024-10-31

Lead Sponsor: Takeda

Target Recruit Count: 245

Registration Number: NCT03589326

Locations: 🇺🇸
Augusta University Georgia Cancer Center, Augusta, Georgia, United States
🇨🇦
Hopital Charles-LeMoyne, Greenfield Park, Quebec, Canada
🇧🇬
University Multiprofile Hospital for Active Treatment Saint Ivan Rilski, Sofia, Sofiya, Bulgaria

and more 89 locations

SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

Phase 2

Conditions: Refractory Multiple Myeloma

Interventions: Drug: Selinexor
Drug: Daratumumab
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2018-07-17

Last Posted Date: 2021-02-04

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 62

Registration Number: NCT03589222

Locations: 🇪🇸
Hospital Germans Trials i Pujol, Badalona, Spain
🇪🇸
Hospital Clinic de Barcelona, Barcelona, Spain
🇪🇸
Hospital ICO de Girona, Girona, Spain

and more 12 locations

Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer

Phase 2

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
Hematopoietic and Lymphoid System Neoplasm
Locally Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Recurrent Malignant Solid Neoplasm

Interventions: Drug: Dexamethasone
Behavioral: Exercise Intervention
Other: Placebo Administration

First Posted Date: 2018-07-11

Last Posted Date: 2024-12-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 99

Registration Number: NCT03583255

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Safety Study of SEA-BCMA in Patients With Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: SEA-BCMA
Drug: dexamethasone
Drug: pomalidomide

First Posted Date: 2018-07-10

Last Posted Date: 2024-12-24

Lead Sponsor: Seagen Inc.

Target Recruit Count: 83

Registration Number: NCT03582033

Locations: 🇺🇸
Holden Comprehensive Cancer Center / University of Iowa, Iowa City, Iowa, United States
🇺🇸
Weill Cornell Medicine, New York, New York, United States
🇺🇸
Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States

and more 10 locations

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

Phase 3

Completed

Conditions: Malignant Neoplasm

Interventions: Drug: Palonosetron Hydrochloride
Drug: Ondansetron Hydrochloride
Drug: Dexamethasone
Drug: Fosaprepitant Dimeglumine
Other: Placebo
Drug: Olanzapine

First Posted Date: 2018-07-05

Last Posted Date: 2023-05-08

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 690

Registration Number: NCT03578081

Locations: 🇺🇸
Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States
🇺🇸
Hurley Medical Center, Flint, Michigan, United States
🇺🇸
Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States

and more 562 locations

Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

Phase 1

Completed

Conditions: Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Philadelphia Chromosome Positive
Recurrent Acute Lymphoblastic Leukemia
t(9;22)
Refractory Acute Lymphoblastic Leukemia
Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Interventions: Drug: Dexamethasone
Drug: Ponatinib Hydrochloride
Biological: Rituximab
Drug: Venetoclax

First Posted Date: 2018-07-03

Last Posted Date: 2024-11-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 11

Registration Number: NCT03576547

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy